Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

Inclusion Criteria: * ITP confirmed by excluding other supervened causes of thrombocytopenia; * Platelet count of less than 30×10\^9/L at enrollment; * Patients who did not achieve a sustained response to treatment with full dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation; Exclusion Criteria: * Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus); * Congestive heart failure; * Severe arrhythmia; * Nursing or pregnant women; * Aspartate aminotransferase and alanine transaminase levels ≥ 3×the upper limit of the normal threshold criteria; * Creatinine or serum bilirubin levels each 1•5 times or more than the normal range; * Active or previous malignancy; * Patients with other diseases were undergoing treatment with immunosuppressants; * Patients with ITP had received rituximab;